The U.S. and European Union osteoporosis drugs market is experiencing growth, and this development can be credited to the growing occurrence rate of osteoporosis illnesses, the rising elderly populace, the rising cases of overweightness, the increasing occurrence of lifestyle-related illnesses, and the rising healthcare expenditure in the U.S. and the EU.
In 2022, the U.S. osteoporosis drugs industry size was valued at USD 6,210.4 million, and the market is projected to surge to USD 9,105.2 million by 2030, growing at a CAGR of 4.90% during the projection period. This is mainly because of the existence of a huge count of market giants, improved healthcare infrastructure, huge expenditure by the government in the healthcare industry, and augmented awareness regarding the illness in the nation.
In 2022, the European Union osteoporosis drugs industry size was valued at USD 2,965.4 million, and this count is additionally projected to surge to USD 4,265.4 million by 2030, growing at a CAGR of 4.65% during the projection period. This is credited to the rising elderly populace, altering lifestyles, fast urbanization, and growing knowledge regarding osteoporosis care in the region.
On the basis of application, the primary osteoporosis category accounts for a larger income share and it will also witness quicker development during the projection period. This is mainly because the mainstream cases that happened are of the primary type, which impacts females after menopause as a result of an unexpected decrease in estrogen production; the loss of bone structure because of the lack of testosterone in males; and the rising elderly populace in the U.S. and the EU.
Osteoporosis results in decreased bone mass and significant loss of bone which increases fracture risk. It impacts individuals of both sexes and all races/ethnicities. For example, in the U.S. alone, there are about 2 million osteoporosis-linked fractures, and the price associated with osteoporosis each year is approximately USD 19 billion.